Data availability
All data needed to evaluate the conclusions in the paper are present in the paper and/or in the Supplementary Material. Additional data related to this paper may be requested from the corresponding author, upon reasonable request by qualified academic investigators.
References
Haroche J, Cohen-Aubart F, Amoura Z (2020) Erdheim-Chester disease. Blood 135(16):1311–1318. https://doi.org/10.1182/blood.2019002766
Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai-Dorfman disease: an overview. J Clin Pathol 73(11):697–705. https://doi.org/10.1136/jclinpath-2020-206733
Razanamahery J, Diamond EL, Cohen-Aubart F, Plate KH, Lourida G, Charlotte F, Hélias-Rodzewicz Z, Goyal G, Go RS, Dogan A, Abdel-Wahab O, Durham B, Ozkaya N, Amoura Z, Emile JF, Haroche J (2020) Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica 105(1):e5–e8. https://doi.org/10.3324/haematol.2019.216937
Cohen Aubart F, Idbaih A, Galanaud D, Law-Ye B, Emile JF, Charlotte F, Donadieu J, Maksud P, Seilhean D, Amoura Z, Hoang-Xuan K, Haroche J (2020) Central nervous system involvement in Erdheim-Chester disease: an observational cohort study. Neurology 95(20):e2746–e2754. https://doi.org/10.1212/WNL.0000000000010748
Adeleye AO, Amir G, Fraifeld S, Shoshan Y, Umansky F, Spektor S (2010) Diagnosis and management of Rosai-Dorfman disease involving the central nervous system. Neurol Res 32(6):572–578. https://doi.org/10.1179/016164109X12608733393836
Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB (2016) Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget 7(51):85430–85436. https://doi.org/10.18632/oncotarget.13397
Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, Baselga J, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O (2015) Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov 5(1):64–71
Janku F, Vibat CR, Kosco K, Holley VR, Cabrilo G, Meric-Bernstam F, Stepanek VM, Lin PP, Leppin L, Hassaine L, Poole JC, Kurzrock R, Erlander MG (2014) BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Oncotarget 5(11):3607–3610. https://doi.org/10.18632/oncotarget.1964
Shen SY, Burgener JM, Bratman SV, De Carvalho DD (2019) Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat Protoc 14(10):2749–2780. https://doi.org/10.1038/s41596-019-0202-2
Schiavo Lena M, Cangi MG, Pecciarini L, Francaviglia I, Grassini G, Maire R, Partelli S, Falconi M, Perren A, Doglioni C (2021) Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor. Virchows Arch 478(6):1215–1219. https://doi.org/10.1007/s00428-020-02942-1
Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, Uhrig S, Hübschmann D, Toprak UH, López C, Hostench XP, Borgoni S, Juraeva D, Pritsch F, Paramasivam N, Balasubramanian GP, Schlesner M, Sahay S, Weniger M, Pehl D, Radbruch H, Osterloh A, Korfel A, Misch M, Onken J, Faust K, Vajkoczy P, Moskopp D, Wang Y, Jödicke A, Trümper L, Anagnostopoulos I, Lenze D, Küppers R, Hummel M, Schmitt CA, Wiestler OD, Wolf S, Unterberg A, Eils R, Herold-Mende C, Brors B, ICGC MMML-Seq Consortium, Wiemann S, Heppner FL (2022) The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun 13(1):2558. https://doi.org/10.1038/s41467-022-30050-y
Franconieri F, Martin-Silva N, de Boysson H, Galateau-Salle F, Emile JF, Bienvenu B, Aouba A (2016) Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: towards the paradigm of combined targeting and immune therapies. Acta Oncol 55(7):930–932. https://doi.org/10.3109/0284186X.2015.1120885
Campochiaro C, Cavalli G, Farina N, Tomelleri A, De Luca G, Dagna L (2022) Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. Ann Rheum Dis 81(1):e11. https://doi.org/10.1136/annrheumdis-2019-216610
Melloul S, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Fraitag S, Terrones N, Riller Q, Chazal T, Héritier S, Moreau A, Kambouchner M, Copin MC, Donadieu J, Taly V, Amoura Z, Haroche J, Emile JF (2019) Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica 104(3):e97–e99. https://doi.org/10.3324/haematol.2018.201194
De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramony Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. https://doi.org/10.1038/ncomms9839
Funding
This study was partly supported by funds from the Italian Ministry of Health (RCR-2021-23671213; RCR_2021_ACC and RC-2022-2023 to RP, Fondazione IRCCS Istituto Neurologico Carlo Besta).
Author information
Authors and Affiliations
Contributions
VP, GB, GF, MF: study concept and design; VP, GB, RP, GF: major role in the acquisition of data; VP, GB, RP, LF, AT, CC, FE, TC, MGC, NPT, AJMF, AC, MB, NA, LGG, LB, MC, GF, MF; analysis and interpretation of the data; VP, GB: drafting the manuscript; VP, GB, RP, LF, AT, CC, FE, TC, MGC, NPT, AJMF, AC, MB, NA, LGG, LB, MC, MP, GF, MF: revision of the manuscript for intellectual content.
Corresponding author
Ethics declarations
Conflicts of interest
The authors report no competing interests relevant to the manuscript.
Ethical standards
Biological studies were performed upon the acquisition of patient’s written informed consent within an ongoing study approved by the Institutional Ethics Committee, in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pieri, V., Berzero, G., Paterra, R. et al. Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease. J Neurol 271, 575–579 (2024). https://doi.org/10.1007/s00415-023-11983-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-023-11983-w